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Transforming Growth  
Factor-β Signaling in Skin:  
Stromal to Epithelial Cross-Talk
Alain Mauviel1
In this issue, Denton et al., describe a mouse model of postnatal deletion of the 
transforming growth factor (TGF)-β receptor type II (TβRII) in skin fibroblasts. 
Using a tamoxifen-dependent inducible Cre-lox strategy, the authors demon-
strate the pivotal role played by TGF-β signaling in fibroblasts during wound heal-
ing. Healing of full-thickness wounds after fibroblast-specific deletion of TβRII 
in the skin was severely impaired and exhibited delayed re-epithelialization. 
This study emphasizes the importance of fibroblasts in mesenchymal–epithelial 
interaction in the skin during wound repair.
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tGF-β signaling: an overview
TGF-β transduces its signal via specific 
cell surface serine/threonine kinase 
receptors, types I and II (TβRI and TβRII). 
These receptors exhibit small cysteine-
rich extracellular regions and intracel-
lular portions consisting mainly of the 
kinase domains. TGF-β binds TβRII, 
forming a heterodimeric complex that 
can recruit and activate TβRI by phos-
phorylating serine and threonine resi-
dues within a region rich in glycine and 
serine residues (GS domain) preceding 
the TβRI kinase domain. Signal transduc-
tion from TGF-β receptors to the nucleus 
is mediated predominantly by ligand-
activated TβRI-dependent phosphory-
lation of cytoplasmic mediators of the 
Smad family (reviewed in Javelaud and 
Mauviel, 2004; Schiller et al., 2004).
tGF-β roles in wound healing:  
more complex than thought?
TGF-β is a prototypic regulator of 
extracellular matrix (ECM) deposition, 
positively regulating the expression of 
components of the ECM and that of pro-
tease inhibitors, including plas minogen 
activator inhibitor-1 or tissue inhibitor 
of metalloproteinases, while inhibiting 
the expression of metalloproteinases in 
fibroblasts. These combined anabolic 
and anticatabolic effects make TGF-β 
a powerful enhancer of wound heal-
ing but also a pathogenic growth factor 
whose continuing signaling may lead 
to the development of tissue fibrosis 
(Verrecchia and Mauviel, 2002, 2004). 
Denton et al. (2009, this issue) used a 
tamoxifen-inducible Cre recombinase 
to delete TβRII in skin fibroblasts in adult 
mice, generating “TβRII–null fib” mice. 
Using a full-thickness wound model 
and ex vivo fibroblast cultures, the 
authors demonstrate that fibroblast-spe-
cific deletion of TβRII profoundly alters 
wound healing. Wounds in TβRII–null 
fib mice exhibited an almost complete 
absence of dermal regeneration, dimin-
ished wound contraction and closure, 
reduced ECM deposition, and delayed 
re-epithelialization and epidermal dif-
ferentiation. Ex vivo experiments dem-
onstrated abnormal migratory capacity 
and impaired myofibroblast differentia-
tion of TβRII-null fibroblasts in response 
to TGF-β, accompanied by a loss of 
contractile properties.
Numerous studies have document-
ed the ability of exogenous TGF-β to 
improve wound healing (reviewed in 
Roberts and Sporn, 1993; Verrecchia 
and Mauviel, 2007). Yet, Smad3-null 
mice paradoxically show accelerated 
cutaneous wound healing compared 
with wild-type mice, characterized by 
rapid re-epithelialization and reduced 
local inflammation (Ashcroft et al., 
1999). Thus, Smad3 may mediate in 
vivo signaling that is inhibitory to 
epithelial wound healing. It is also 
possible that suppression of Smad3 
levels may occur during normal 
wound healing. This study did not dis-
tinguish the relative contributions of 
each cellular compartment involved 
in wound healing because no tissue-
specific, conditional deletion of 
Smad3 was performed. Indeed, the 
specific role played by TGF-β during 
mesenchymal–epithelial cross-talk has 
remained rather enigmatic in the con-
text of physio logical processes such as 
wound healing. Remarkably, the work 
by Denton et al. addresses this issue 
and demonstrates that abolishing TGF-β 
signaling post natally specifically in 
fibroblasts inhibits healing of excisional 
skin wounds in adult mice, with mark-
edly attenuated dermal scar forma-
tion, defective wound contraction, and 
reduced epidermal proliferation.
molecular mechanisms affecting  
skin wound repair:  
does tGF-β orchestrate all this?
A number of studies have addressed 
the molecular mechanisms underly-
ing epidermal wound healing. For 
example, Parks and co-workers showed 
initially that keratinocyte migration 
leading to wound closure was depen-
dent on matrix metallo proteinase 
(MMP) activity induced by keratinocyte 
contact with the wound bed (Pilcher 
et al., 1997). Such contacts generate 
collagen–integrin signaling, resulting 
in MMP-1 activation in keratin ocytes 
and sub sequent degradation of type I 
collagen, a necessary step for direction-
ality of keratinocyte migration and effi-
cient wound closure.
Using a skin-equivalent model of 
human keratinocytes and immortal-
ized c-Jun- or JunB-deficient fibroblasts, 
Szabowski et al. (2000) identified the 
balance in cJun and JunB expression in 
fibroblasts as essential for keratinocyte 
proliferation and differentiation to form 
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a three-dimensionally organized epith- 
elium. Fibroblast -derived keratino cyte 
growth factor (KGF) and GM-CSF could 
be identified as key regulators of the 
paracrine loop responsible for the fine-
tuned balance of keratinocyte prolifera-
tion and differentiation to form an intact 
epidermis. Remarkably, after conditional 
deletion of JunB in skin fibroblasts (Florin 
et al., 2006), excisional wounding 
resulted in a phenotype similar to that 
described by Denton et al. in this issue, 
characterized by delayed wound closure 
and abnormal dermal collagen reorgani-
zation. Also, JunB∆/∆ fibroblasts, unlike 
TβRII-null fibroblasts, exhibited reduced 
contractile activity, although with no 
obvious loss of α-smooth muscle actin.
Remarkably, TGF-β is an important 
regulator of JUN expression, specifi-
cally inducing expression of JUNB in 
fibroblasts and that of both JUNB and 
cJUN in keratinocytes, with the latter 
leading to enhanced MMP1 expression 
(Mauviel et al., 1993, 1996; Verrecchia 
et al., 2001a,b). How TGF-β signaling 
in fibroblasts is able to regulate epi-
dermal wound closure remains to be 
elucidated, yet it may be hypothesized 
that TGF-β-dependent JUNB expression 
regulates the expression of soluble fac-
tors such as KGF or GM-CSF, or that of 
MMP-1 in keratinocytes, all capable of 
regulating epidermal homeostasis and 
repair. Another possibility resides in the 
fact that TGF-β is capable of regulat-
ing its own expression via induction of 
activator protein-1 complexes (Kim et 
al., 1990; Van Obberghen-Schilling et 
al., 1988). TβRII deletion in fibroblasts 
is thus likely to reduce the autocrine 
expression of TGF-β during wound 
repair. In turn, this effect may reduce 
MMP-1 production by adjacent kerati-
nocytes, thereby altering their capacity 
to migrate and close the wound.
Reconciling all the above stud-
ies in an integrative approach would 
provide helpful clues to understand-
ing the mechanisms of skin repair.
Fibroblast signaling of adjacent epithelial 
cells: cross-talk at work
Another level of complexity arises 
from the fact that fibroblasts are not all 
equal; conditional inactivation of the 
TGF-β type II receptor gene in mouse 
fibroblasts (Tgfbr2fspKO) resulted in 
intraepithelial neoplasia in prostate and 
invasive squamous cell carcinoma of 
the forestomach but not in other tissues 
(Bhowmick et al., 2004). In another 
study, tissue-specific conditional knock-
out of the TGF-β type II receptor gene in 
mouse mammary fibroblasts led to defec-
tive mammary duct development (Cheng 
et al., 2005). Furthermore, Tgfbr2fspKO 
mammary fibroblasts transplanted with 
mammary carcinoma cells promoted 
growth and invasion in a model of tum-
origenesis in mice. It appears, therefore, 
that TGF-β signaling in fibroblasts is 
critical for the oncogenic potential and 
growth of adjacent epithelia in selected 
tissues (Bhowmick and Moses, 2005; 
Dennler et al., 2008). Functional dif-
ferences between fibroblasts in differ-
ent organs may explain this specificity, 
which remains to be characterized.
The current study by Denton et al. 
(2009) demonstrates that in skin wound 
repair, TGF-β signaling in fibroblasts is 
important not only for ECM produc-
tion by fibroblasts and for their trans-
differentiation into myofibroblasts 
but also for adjacent keratinocytes. 
Furthermore, the authors identify con-
stitutive activation of extracellular 
signal–related kinase signaling in 
TβRII-null fibroblasts as leading to high 
expression of CTGF, a gene considered 
to be a typical TGF-β/Smad response 
gene. This adds a new level of com-
plexity to the understanding of cell sig-
naling, and it exemplifies the difficul-
ties in targeting TGF-β signaling while 
controlling for the side effects that arise 
from disruption of cross-talk with other 
signaling pathways, such as mitogen-
activated protein kinases (reviewed 
in Javelaud and Mauviel, 2005). The 
precise spatiotemporal role of TGF-β-
initiated signals, as well as their effect 
on other signal transduction cascades 
and on adjacent tissues, remains to be 
elucidated. Only with this information 
can effective therapeutic intervention 
against TGF-β be envisioned in clini-
cal settings, such as in tissue fibrosis, 
wound healing, and cancer.
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Getting Stronger: The Relationship 
Between a newly Identified Virus  
and Merkel Cell Carcinoma
Christopher B. Buck1 and Douglas R. Lowy1
Merkel cell carcinoma (MCC) is an aggressive skin cancer that develops in individu-
als who are over the age of 50 or immunosuppressed. DnA from a new polyoma-
virus, MCPyV, was recently shown to be clonally integrated in several MCC cases. 
In this issue, Becker et al. demonstrate that MCPyV DnA can be isolated from 85% 
of primary European MCC specimens and their metastases, and Garneski et al. 
present data indicating that the percentage of Australian MCC cases containing 
MCPyV may be lower than that of north American cases. These reports support 
the possibility that MCPyV is etiologically involved in at least some cases of MCC.
Journal of Investigative Dermatology (2008), 129, 9–11. doi:10.1038/jid.2008.302
Earlier this year, genetic analysis of 
Merkel cell carcinomas (MCCs) revealed 
the existence of a previously unidentified 
human polyomavirus (Feng et al., 2008). 
DNA sequences from the virus, desig-
nated Merkel cell carcinoma polyoma-
virus (MCPyV), were detected in 8 of 
10 MCC tumor specimens but in only 
4 of 25 (16%) control skin samples. In 
this issue of the Journal of Investigative 
Dermatology, two letters confirm and 
significantly extend these findings to 
additional cases of MCC (Becker et al., 
2008; Garneski et al., 2008). Using PCR-
based analysis, Becker et al. found that 
45 of 53 (85%) MCC cases from a cen-
ter in Europe contained MCPyV DNA. 
Garneski et al. detected MCPyV DNA 
in 11 of 16 (69%) North American and 
5 of 21 (24%) Australian MCC speci-
mens. The frequent detection of MCPyV 
DNA in European cases of MCC was 
also recently confirmed by Kassem et al. 
(2008). The clear confirmation that most 
MCC tumors carry MCPyV sequences 
represents an important step in address-
ing the intriguing hypothesis that the 
virus is a key etiologic agent behind 
MCC and perhaps other forms of cancer.
clinical and epidemiological 
features of mcc
Merkel cells were identified in 1875 as a 
distinctive, histologically translucent cell 
type associated with epidermal nerve 
endings (Halata et al., 2003). At the 
time of their discovery, it was reasoned 
that Merkel cells might participate in the 
sensation of mechanical stimuli. Like 
melanocyte precursors, the precursors of 
Merkel cells are thought to migrate dur-
ing development from the neural crest to 
their ultimate home in the basal layer of 
the epidermis and the outer root sheath 
of hair follicles (Szeder et al., 2003). 
Although Merkel cells do exhibit a num-
ber of neuroendocrine features, such as 
cytoplasmic neuropeptide–containing 
granules, the idea that they are directly 
involved in mechanosensation remains 
inferential (Boulais and Misery, 2008).
Approximately 1,500 new MCC cases 
are diagnosed in the United States each 
year (Lemos and Nghiem, 2007). MCC is 
thus a rare form of skin cancer compared 
with the more than 1 million cases of 
nonmelanoma skin cancer and roughly 
60,000 cases of melanoma per year in 
the same population. However, MCC is 
an aggressive, fast-growing malignancy 
that ultimately kills about one-third of 
those diagnosed with the disease. It is also 
important to note an alarming threefold 
increase in the incidence of MCC between 
1986 and 2001 (Hodgson, 2005).
MCC is more common in lighter-
skinned individuals, is associated with a 
history of sun exposure, and occurs pre-
dominantly on sun-exposed areas, such 
as the face (especially around the eyes) 
and extremities (Miller and Rabkin, 1999). 
Limited mutational screening of cellular 
genes in MCC identified the presence of 
two C-to-T transitions, characteristic of 
UVB-induced mutation, in one MCC cell 
line (Van Gele et al., 2000). Garneski et 
al. (2008, this issue) speculate that the 
smaller percentage of MCPyV in the 
Australian MCC cases they studied (24% 
vs. 69% in the North American cases, 
P = 0.009) might be related to the greater 
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